Israeli drugmaker Teva Pharmaceutical Industries has announced US Food and Drug Administration (FDA) approval and launch of a generic version of Saxenda (liraglutide injection).

Novo Nordisk's Martin Holst Lange preveiwed the company's obesity pill, while OpenAI launches new initiative to speed up scientific discovery.

Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.

President Trump urged pharmaceutical companies to publicly prove that their Covid-19 products work, saying in a Truth Social ...